190 related articles for article (PubMed ID: 32687499)
1. The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.
Gostelie R; Stegeman I; Berkers G; Bittermann J; Ligtenberg-van der Drift I; Kipshagen PV; de Winter-de Groot K; Speleman L
PLoS One; 2020; 15(7):e0235638. PubMed ID: 32687499
[TBL] [Abstract][Full Text] [Related]
2. Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.
Vreede CL; Berkhout MC; Sprij AJ; Fokkens WJ; Heijerman HG
J Cyst Fibros; 2015 May; 14(3):412-3. PubMed ID: 25169789
[TBL] [Abstract][Full Text] [Related]
3. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
van de Peppel IP; Doktorova M; Berkers G; de Jonge HR; Houwen RHJ; Verkade HJ; Jonker JW; Bodewes FAJA
J Cyst Fibros; 2019 Mar; 18(2):286-293. PubMed ID: 30279125
[TBL] [Abstract][Full Text] [Related]
4. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
5. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
6. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
[TBL] [Abstract][Full Text] [Related]
7. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
8. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
[TBL] [Abstract][Full Text] [Related]
9. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation.
Burghard MM; Berkers GG; Ghijsen SS; Hollander-Kraaijeveld FF; de Winter-de Groot KK; van der Ent CK; Heijerman HH; Takken TT; Hulzebos HE
Pediatr Pulmonol; 2020 Jun; 55(6):1400-1405. PubMed ID: 32233113
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
13. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial.
Davies JC; Wainwright CE; Sawicki GS; Higgins MN; Campbell D; Harris C; Panorchan P; Haseltine E; Tian S; Rosenfeld M
Am J Respir Crit Care Med; 2021 Mar; 203(5):585-593. PubMed ID: 33023304
[No Abstract] [Full Text] [Related]
14. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
15. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
[TBL] [Abstract][Full Text] [Related]
16. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.
Grasemann H; Gonska T; Avolio J; Klingel M; Tullis E; Ratjen F
J Cyst Fibros; 2015 Nov; 14(6):727-32. PubMed ID: 26168933
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.
Guimbellot J; Solomon GM; Baines A; Heltshe SL; VanDalfsen J; Joseloff E; Sagel SD; Rowe SM;
J Cyst Fibros; 2019 Jan; 18(1):102-109. PubMed ID: 29685811
[TBL] [Abstract][Full Text] [Related]
18. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC;
Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024
[TBL] [Abstract][Full Text] [Related]
19. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
[TBL] [Abstract][Full Text] [Related]
20. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.
Stallings VA; Sainath N; Oberle M; Bertolaso C; Schall JI
J Pediatr; 2018 Oct; 201():229-237.e4. PubMed ID: 30029855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]